Genscript

Company Overview

Founded in 2002, GenScript manufactures and markets genomic and proteomic tools for the life science industry. The main business areas include Life science services and products, Biologics development services, Industrial synthetic biology products, and Cell therapy.

The subsidiary of GenScript group, Bestzyme Biotech Corporation (“Bestzyme”), is engaged in the synthetic biology business. Life science research services include DNA synthesis, genetic analysis and engineering services, recombinant protein production, peptide synthesis and customized antibody production, and biochemical reagents and research kits.

The DNA synthesis market is important to GenScript, and it maintains a leading position in terms of market share. GenScript has also developed several other businesses related to DNA synthesis, including DNA-sequencing services for confirming the fidelity of the sequence for DNA synthesis constructs and the production of downstream proteins from the synthesized genes.

GenScript is leveraging its capabilities to produce downstream synthetic biology products, including industrial enzymes. This business is a key growth strategy for the company, as it is complementary to its legacy business of developing and synthesizing new genes. Industrial enzymes launched as part of this effort include alpha-amylase, glucose oxidase, fungal alpha-amylase, and prolyl endopeptidase. Fungal alpha-amylase is a key enzyme for producing maltose syrup and for use in steamed bread processing. Prolyl endopeptidase is used as a beer clarificant to replace the traditional chemical clarifying agent.

Financial Highlights (FY 2023)